Microsoft is developing a Chinese-speaking, AI chatbot for diabetic patients

Microsoft Nova

Microsoft China and Novo Nordisk, a leading healthcare company specializing in diabetes, today announced the partnership to develop a Chinese-speaking, AI chatbot for diabetic patients. This new AI chatbot will make use of Microsoft’s Azure cloud and AI services and Novo Nordisk’s expertise and experience in diabetes. This chatbot will help diabetic patients to improve their knowledge of the disease for better self-management. The chatbot will be launched in early 2021 on Novo Nordisk’s digital patient support platforms.

Christine Zhou, Senior Vice President and President of Novo Nordisk Region China, said, “Across our hundred-year legacy of caring for and tackling diabetes, Novo Nordisk has witnessed how diabetes has become one of the world’s biggest health challenges. We believe that innovations in medicine should be accompanied by a patient-centric philosophy that extends to empowering patients to manage their disease. We hope to do just that by providing patients with a more in-depth understanding of the disease’s risks and related knowledge, and improving their quality of life with our new Chinese-speaking chatbot.”

Alain Crozier, Microsoft Corporate Vice President, Chairman and CEO of Greater China Region, said, “All industries, including healthcare, are accelerating their pace of digital transformation by using digital technologies to respond to, and recover from, this pandemic. Often, they do it in ways that will make them stronger, more creative and more resilient. Microsoft is excited to partner with industry leaders such as Novo Nordisk to help with the prevention and treatment of diabetes using Microsoft’s AI and cloud services. By driving the use of advanced technologies across industries, Microsoft hopes to help businesses and individuals embrace innovation and enhance resilience in the face of the challenges – and opportunities – that lie ahead.”

Source: Microsoft

Some links in the article may not be viewable as you are using an AdBlocker. Please add us to your whitelist to enable the website to function properly.

Related
Comments